Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension.
Mason W FreemanYuan-Di HalvorsenWilliam MarshallMackenzie PaterJon IsaacsohnCatherine PearceBrian MurphyNicholas AlpAjay SrivastavaDeepak L BhattMorris J Brownnull nullPublished in: The New England journal of medicine (2022)
Patients with treatment-resistant hypertension who received baxdrostat had dose-related reductions in blood pressure. (Funded by CinCor Pharma; BrigHTN ClinicalTrials.gov number, NCT04519658.).